The GnRH antagonist protocol is widely used in clinical practice because it can shorten the stimulation duration, reduce the incidence of ovarian hyperstimulation syndrome, and improve adenomyosis and endometriosis [7–9]. This evidence concerns the gene GNRH1 and adenomyosis.